Eli Lilly and Co
(BSP:LILY34)
R$
195.85
+4.54 (+2.37%)
Market Cap: 5.19 Tn
Enterprise Value: 5.43 Tn
PE Ratio: 38.33
PB Ratio: 30.06
GF Score: 95/100 Eli Lilly and Company at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2026 / 05:50PM GMT
Release Date Price:
R$195.85
(+2.37%)
Terence Flynn
Morgan Stanley & Co Ltd - Analyst
All right. Thanks so much everyone. I'm Terence Flynn, Morgan Stanley's US biopharma analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
This afternoon, I'm very pleased to be hosting Eli Lilly. Joining us today from the company is Ilya Yuffa, who is the company's Executive Vice President and President, of Lilly USA and global customer capabilities. But I appreciate the time this afternoon.
Ilya Yuffa
Eli Lilly and Company - Executive Vice President, President of Lilly International
Yes. Great to be here.
Terence Flynn;Ilya Yuffa
Morgan Stanley & Co Ltd - Analyst;Eli Lilly and Company - Executive Vice
We're really looking forward to the discussion.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot